Colloidal carriers diverge depending on their composition, ability to incorporate drugs and applicability, but the common feature is the small average particle size. Among the carriers with the potential nanostructured drug delivery application there are SLN and NLC. These nanostructured systems consist of complex lipids and highly purified mixtures of glycerides having varying particle size. Also, these systems have shown physical stability, protection capacity of unstable drugs, release control ability, excellent tolerability, possibility of vectorization, and no reported production problems related to large-scale. Several production procedures can be applied to achieve high association efficiency between the bioactive and the carrier, depending on the physicochemical properties of both, as well as on the production procedure applied. The whole set of unique advantages such as enhanced drug loading capacity, prevention of drug expulsion, leads to more flexibility for modulation of drug release and makes Lipid-based nanocarriers (LNCs) versatile delivery system for various routes of administration. The route of administration has a significant impact on the therapeutic outcome of a drug. Thus, the non-invasive routes, which were of minor importance as parts of drug delivery in the past, have assumed added importance drugs, proteins, peptides and biopharmaceuticals drug delivery and these include nasal, buccal, vaginal and transdermal routes. The objective of this paper is to present the state of the art concerning the application of the lipid nanocarriers designated for non-invasive routes of administration. In this manner, this review presents an innovative technological platform to develop nanostructured delivery systems with great versatility of application in non-invasive routes of administration and targeting drug release.

胶体载体根据其组成，结合药物的能力和适用性而有所不同，但共同的特征是平均粒径小。在具有潜在的纳米结构药物递送应用的载体中，有SLN和NLC。这些纳米结构系统由复杂的脂质和具有不同粒径的甘油酯的高度纯化的混合物组成。而且，这些系统显示出物理稳定性，不稳定药物的保护能力，释放控制能力，优异的耐受性，载体化的可能性，并且没有报道的大规模生产问题。根据两者的物理化学性质以及所采用的生产程序，可以采用几种生产程序来实现生物活性剂和载体之间的高缔合效率。整套独特的优势，例如增强的载药量，防止药物排出，带来更大的药物释放调节灵活性，并使基于脂质的纳米载体（LNC）成为多种给药途径的通用递送系统。给药途径对药物的治疗效果有重大影响。因此，在过去作为药物输送的一部分次要的非侵入性途径中，假定药物，蛋白质，肽和生物药物的药物输送更加重要，这些途径包括鼻，颊，阴道和经皮途径。本文的目的是提出有关指定用于非侵入性给药途径的脂质纳米载体的应用的最新技术。以这种方式，